[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Tadokoro M, Masuda H, Fujii Y, Kobayashi T, Kageyama Y, Kihara K: Late relapse of stage I testicular seminoma metastatic to just a para-ureteropelvic region. Int J Urol; 2004 Nov;11(11):1044-6
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late relapse of stage I testicular seminoma metastatic to just a para-ureteropelvic region.
  • Computed tomography scans of the abdomen showed a bulky tumor around the ureteropelvic region without para-aortic lymph node enlargement, but did not show a clear distinction between a recurrence of the testicular tumor and an invasive ureteral tumor.
  • After the patient underwent two cycles of chemotherapy with cisplatin and etoposide, the tumor mass decreased by approximately 60% and beta-hCG levels returned to normal.
  • We then performed a resection of the residual tumor involving the upper ureter and left kidney and a retroperitoneal lymph node dissection under a clinical diagnosis of recurrence of the testicular tumor.
  • [MeSH-major] Kidney Pelvis / pathology. Neoplasm Recurrence, Local / pathology. Seminoma / pathology. Testicular Neoplasms / pathology. Ureteral Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chorionic Gonadotropin, beta Subunit, Human / blood. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Hydronephrosis / etiology. Male

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15509217.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Denschlag D, Ulrich U, Emons G: The diagnosis and treatment of endometrial cancer: progress and controversies. Dtsch Arztebl Int; 2010 Aug;108(34-35):571-7
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnosis and treatment of endometrial cancer: progress and controversies.
  • BACKGROUND: Endometrial carcinoma is the fourth most common type of cancer among women in Germany, with more than 11 000 newly diagnosed cases each year.
  • On the basis of risk stratification (e.g., by tumor stage and histological differentiation grade), women who are judged to be at high risk (FIGO Stage IB and above, Grade 3) should undergo not just hysterectomy and adnexectomy, but also systematic pelvic and para-aortic lymphadenectomy.
  • The additional or alternative administration of chemotherapy is a particular consideration for women at high risk, although the pertinent clinical trials to date have yielded conflicting evidence on this point.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / therapy. Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / therapy. Cystadenoma, Serous / diagnosis. Cystadenoma, Serous / therapy. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / therapy. Evidence-Based Medicine. Neoplasms, Hormone-Dependent / diagnosis. Neoplasms, Hormone-Dependent / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemoradiotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dtsch Arztebl Int. 2010 May;107(20):353-9 [20539807.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):36-44 [16330675.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1510-7 [9809732.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD001040 [10796737.001]
  • [Cites] Lancet. 2010 Apr 3;375(9721):1165-72 [20188410.001]
  • [Cites] Lancet. 2010 Mar 6;375(9717):816-23 [20206777.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):788-92 [20065186.001]
  • [Cites] Int J Gynecol Cancer. 2009 Nov;19(8):1465 [19893425.001]
  • [Cites] Obstet Gynecol. 2009 Sep;114(3):523-9 [19701030.001]
  • [Cites] J Clin Oncol. 2009 Jul 20;27(21):3547-56 [19546404.001]
  • [Cites] Cochrane Database Syst Rev. 2009;(2):CD000402 [19370558.001]
  • [Cites] Obstet Gynecol. 2009 Feb;113(2 Pt 1):319-25 [19155901.001]
  • [Cites] Gynecol Oncol. 2009 Feb;112(2):415-21 [18973934.001]
  • [Cites] Lancet. 2009 Jan 10;373(9658):137-46 [19070891.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 3;100(23):1707-16 [19033573.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2 Suppl):S101-4 [18804267.001]
  • [Cites] Gynecol Oncol. 2008 Apr;109(1):11-8 [18304622.001]
  • [Cites] Int J Gynecol Cancer. 2008 Mar-Apr;18(2):255-61 [17624991.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):226-33 [17996926.001]
  • [Cites] Gynecol Oncol. 2007 Aug;106(2):282-8 [17662377.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):266-71 [16868539.001]
  • [Cites] Lancet. 2000 Apr 22;355(9213):1404-11 [10791524.001]
  • [Cites] Curr Opin Obstet Gynecol. 2006 Jun;18(3):245-52 [16735822.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(2):CD003916 [17443533.001]
  • (PMID = 21904591.001).
  • [ISSN] 1866-0452
  • [Journal-full-title] Deutsches Ärzteblatt international
  • [ISO-abbreviation] Dtsch Arztebl Int
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3167060
  •  go-up   go-down


3. Newsom-Davis T, Poulter D, Gray R, Ameen M, Lindsay I, Papanikolaou K, Butler-Manuel S, Christmas T, Townsend P, Seckl M: Case report: malignant teratoma of the uterine corpus. BMC Cancer; 2009;9:195
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six months after surgery she relapsed with para-aortic lymphadenopathy and was treated with a taxane, etoposide and cisplatin-containing chemotherapy regimen followed by retroperitoneal lymph node dissection.
  • CONCLUSION: In this report we discuss the aetiology, diagnosis and management of uterine teratomas, and review previous case studies.
  • [MeSH-major] Teratoma / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Hysterectomy. Lymphatic Diseases / etiology. Lymphatic Metastasis. Neoplasm Metastasis. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2003 May;53(5):327-31 [12713570.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1169-75 [15026797.001]
  • [Cites] Obstet Gynecol. 1972 Nov;40(5):686-91 [5083218.001]
  • [Cites] N Engl J Med. 1975 Jan 9;292(2):63-6 [162806.001]
  • [Cites] Histopathology. 1979 Jul;3(4):339-45 [468134.001]
  • [Cites] Gynecol Oncol. 1985 May;21(1):106-10 [3988122.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1578-83 [18453518.001]
  • [Cites] Acta Obstet Gynecol Scand. 1998 Oct;77(9):936-8 [9808385.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):216-8 [15972426.001]
  • [Cites] Ultrasound Obstet Gynecol. 2007 Apr;29(4):477-8 [17330830.001]
  • [Cites] Ann Diagn Pathol. 2007 Aug;11(4):293-6 [17630116.001]
  • [Cites] Obstet Gynecol. 2007 Aug;110(2 Pt 2):491-3 [17666639.001]
  • [Cites] Int J Gynecol Cancer. 2008 Jan-Feb;18(1):43-50 [17466047.001]
  • [Cites] Kurume Med J. 1993;40(3):153-8 [8139215.001]
  • (PMID = 19538751.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2709639
  •  go-up   go-down


Advertisement
4. Stryker JA, Mortel R: Survival following extended field irradiation in carcinoma of cervix metastatic to para-aortic lymph nodes. Gynecol Oncol; 2000 Dec;79(3):399-405
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival following extended field irradiation in carcinoma of cervix metastatic to para-aortic lymph nodes.
  • OBJECTIVE: Our goal was to determine survival after extended-field treatment of para-aortic lymph node (PALN) metastasis.
  • The diagnosis in 34 patients was by operative staging and in 1 by CT scan and fine-needle aspiration biopsy.
  • Twelve patients had microscopic PALN metastasis (PALN1) and 23 had grossly enlarged lymph nodes (PALN2).
  • The management approach in this series in stage IB was as follows: If PALN metastasis was identified at exploration for radical hysterectomy, the procedure was aborted and extended-field RT administered.
  • The value of chemotherapy for PALN metastasis remains to be defined but results from clinical trials suggest that cisplatin-based chemotherapy may be beneficial.
  • [MeSH-minor] Aorta. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 11104609.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


5. Karimi Zarchi M, Akhavan A, Fallahzadeh H, Gholami H, Dehghani A, Teimoori S: Outcome of cervical cancer in Iranian patients according to tumor histology, stage of disease and therapy. Asian Pac J Cancer Prev; 2010;11(5):1289-91
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of cervical cancer in Iranian patients according to tumor histology, stage of disease and therapy.
  • The purpose of this study was to measure outcome of treated cervical cancer cases in Yazd since 2002 to 2009, according to pathology, stage of disease, lymph node involvement and therapy.
  • In first months, survival was the same in both pathology types, but because of the higher stages of squamous cell carcinomas in comparison with adenocarcinomas, their overall rate was lower.
  • Stage IIB and IIIB survival rates were 90.9% and 30.8%, respectively, and rates with and without lymph node involvement were 64.8% and 80.1%.
  • With para-aortic lymph node involvement, the rate was 85.8% (mean of 65.3 months).
  • The relationship with lymph node involvement is weak.
  • Survival of women receiving chemotherapy was lower than after surgery.
  • Our findings showed an importance of diagnosis in primary stages and surgical resection of pelvic and para-aortic lymph nodes.
  • [MeSH-major] Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Anemia / complications. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Cross-Sectional Studies. Disease-Free Survival. Female. Humans. Iran. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21198279.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


6. Nakamura K, Nakamura T, Kurachi K, Fukazawa A, Hayashi T, Nakajima A, Suzuki S, Konno H: [A case of sigmoid colon cancer with metastases of para-aortic lymph nodes treated with curative resection after irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy]. Gan To Kagaku Ryoho; 2008 Jun;35(6):1017-20
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of sigmoid colon cancer with metastases of para-aortic lymph nodes treated with curative resection after irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].
  • Abdominal CT revealed metastases to para-aortic lymph node, so our diagnosis was unresectable sigmoid colon cancer.
  • Two weeks after surgery, she underwent a 1-week chemotherapy regimen (CPT-11 80 mg/m(2)/week+5-FU 2,000 mg/m(2)/week+l-LV 250 mg/m(2)/week) modified AIO regimen combined irinotecan for 3 weeks, followed by a 1-week rest interval as one course.
  • Throughout the period of treatment, there was no adverse event, and this regimen has been maintained for 5 courses.
  • After 5 courses of chemotherapy, primary tumor and metastases to para-aortic lymph nodes were remarkably reduced on colonoscopy and abdominal CT.
  • This combination therapy may well be useful for advanced colon cancer patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aorta / pathology. Camptothecin / analogs & derivatives. Fluorouracil / therapeutic use. Leucovorin / therapeutic use. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Metastasis / radiography. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633237.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Takeda K, Uehara M, Tei N, Shimizu K, Imazu T, Yoshimura K, Kiyohara H: [A case of retroperitoneal myxofibrosarcoma]. Hinyokika Kiyo; 2009 Nov;55(11):711-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 63-year-old man presented to our hospital suffering from dull pain in his right flank and general malaise.Abdominal computed tomography (CT) revealed a 21X14 cm retroperitoneal tumor adjacent to the right kidney.
  • Histopathological diagnosis was high-grade myxofibrosarcoma.
  • Eleven months after the original tumor excision, CT revealed lymph node metastasis dorsal to the inferior vena cava,which was also removed.
  • Because he refused to receive adjuvant chemotherapy,he was observed for 2 months until CT revealed multiple liver metastases and para-aortic lymph node metastasis.
  • He underwent 1 cycle of combined chemotherapy with doxorubicin and carboplatin,but metastatic lesions grew larger rapidly and his general state became too poor to continue chemotherapy.
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19946191.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 15
  •  go-up   go-down


8. Abali H, Eren OO, Erman M, Uner AH, Kose F, Guler N: Coincidental detection of T-cell rich B cell lymphoma in the para-aortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer: a case report. Int J Gynecol Cancer; 2003 Sep-Oct;13(5):687-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coincidental detection of T-cell rich B cell lymphoma in the para-aortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer: a case report.
  • The diagnosis of cervical squamous cell carcinoma with concurrent T-cell rich B cell lymphoma in dissected lymph nodes has not been reported to our knowledge.
  • Type III hysterectomy, bilateral salpingo-oophorectemy, bilateral pelvic, para-aortic lymph node dissections were performed.
  • Pathologic examination revealed a T-cell rich B cell lymphoma in some lymph nodes beside squamous cell carcinoma in several of others.
  • Six cycles of CHOP (cyclophosphamide, adriamycin, vincristine, and prednisolon) chemotherapy for the lymphoma and concomitant pelvic chemoradiotherapy with cisplatin for cervical cancer were given.
  • In this rare coincidence, the best available therapy for each of the diseases should be considered individually.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Lymph Nodes / pathology. Lymphoma, B-Cell / pathology. Neoplasms, Multiple Primary / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Immunohistochemistry. Lymph Node Excision / methods. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Radiotherapy, Adjuvant. Risk Assessment. T-Lymphocytes / pathology. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Int J Gynecol Cancer. 2015 Jul;25(6):1142 [26098094.001]
  • (PMID = 14675356.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Duplicate Publication; Journal Article; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


9. Tsujie M, Shibata N, Nomura T, Tanaka T, Morimoto T, Fujita S, Kitani K, Nakahira S, Okuda H, Takeda M: [A patient with stage IVb small cell carcinoma of the esophagus who survived 23 months after systemic cancer chemotherapy]. Gan To Kagaku Ryoho; 2003 Feb;30(2):271-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A patient with stage IVb small cell carcinoma of the esophagus who survived 23 months after systemic cancer chemotherapy].
  • A computed tomography scan showed para-aortic lymph node swelling and multiple liver metastases.
  • Treatment with chemotherapy of CDDP and 5-FU showed clinical complete remission.
  • However, the patient died of paraaortic lymph node metastasis, recurrence of the original lesion, multiple liver metastasis and brain metastasis 23 months after diagnosis.
  • However, if remission is achieved by chemotherapy as in this case, a better prognosis is possible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Esophageal Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Etoposide / administration & dosage. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Survivors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12610878.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen; VP-P protocol
  • [Number-of-references] 14
  •  go-up   go-down


10. Nelsen LL, Muirhead DM, Bell MC: Ovarian small cell carcinoma, hypercalcemic type exhibiting a response to high-dose chemotherapy. S D Med; 2010 Nov;63(11):375-7
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian small cell carcinoma, hypercalcemic type exhibiting a response to high-dose chemotherapy.
  • A gravida 2, para 2 25-year-old woman three months post-partum presented to her primary physician with abdominal pain and bloating; a 20-cm complex cystic pelvic mass was identified by ultrasound.
  • Immunohistochemical stains revealed the neoplasm to be focally positive for keratin and negative for inhibin.
  • The final diagnosis rendered was small cell carcinoma of the ovary, hypercalcemic type.
  • Further staging revealed para-aortic lymph node involvement (stage IIIC).
  • Current literature suggests a very poor prognosis for these neoplasms despite aggressive therapy, with an overall survival rate of 10 percent.
  • Rare response has been noted, however, with high-dose chemotherapy followed by autologous peripheral blood stem cell transplant.
  • Our patient underwent a rigorous chemotherapeutic regimen followed by peripheral blood stem cell transplant, and as of August 2010, (17 months after initial diagnosis), the patient has had no recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / pathology. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Female. Genes, BRCA1. Humans. Hypercalcemia / etiology. Lymphatic Metastasis. Neoplasm Staging. Paraneoplastic Syndromes. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - Ovarian small cell carcinoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21117517.001).
  • [ISSN] 0038-3317
  • [Journal-full-title] South Dakota medicine : the journal of the South Dakota State Medical Association
  • [ISO-abbreviation] S D Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; CCE protocol
  •  go-up   go-down


11. Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutch DG, Powell MA, Grigsby PW: Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol; 2010 Apr 20;28(12):2108-13
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.
  • PURPOSE A previous retrospective study demonstrated that positron emission tomography with [(18)F]fluorodeoxyglucose (FDG-PET) was more sensitive than computed tomography for lymph node staging in patients with cervical cancer; the findings on FDG-PET were strongly associated with progression-free survival.
  • Therefore, a prospective cohort study was initiated to evaluate FDG-PET lymph node staging in a larger patient population.
  • All 560 patients with cervical cancer underwent pretreatment FDG-PET lymph node staging.
  • Treatment included surgery alone, surgery and postoperative radiation therapy, and definitive radiation or combination radiation and chemotherapy.
  • Results Overall, 47% of patients had lymph node involvement by FDG-PET at diagnosis.
  • The frequency of lymph node metastasis increased with clinical stage and was similar to that in historical surgical series.
  • Within a stage, patients with PET-positive lymph nodes had significantly worse disease-specific survival than those with PET-negative lymph nodes (P < .001).
  • Disease-specific survival was stratified into distinct groups based on the most distant level of PET-detected nodal disease (none, pelvic, para-aortic, or supraclavicular; P < .001).
  • The hazard ratios for disease recurrence increased incrementally based on the most distant level of nodal disease: pelvic 2.40 (95% CI, 1.63 to 3.52), para-aortic 5.88 (95% CI, 3.80 to 9.09), and supraclavicular 30.27 (95% CI 16.56 to 55.34).
  • [MeSH-major] Fluorodeoxyglucose F18. Lymph Nodes / radionuclide imaging. Neoplasm Staging / methods. Positron-Emission Tomography. Radiopharmaceuticals. Uterine Cervical Neoplasms / radionuclide imaging
  • [MeSH-minor] Chemotherapy, Adjuvant. Chi-Square Distribution. Female. Gynecologic Surgical Procedures. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Predictive Value of Tests. Proportional Hazards Models. Prospective Studies. Radiotherapy, Adjuvant. Recurrence. Registries. Risk Assessment. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20308664.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


12. Tran BN, Grigsby PW, Dehdashti F, Herzog TJ, Siegel BA: Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. Gynecol Oncol; 2003 Sep;90(3):572-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix.
  • PURPOSE: The objective was to evaluate the frequency and prognostic significance of occult supraclavicular lymph node metastases identified by 2-[(18)F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) in patients with cervical carcinoma.
  • PATIENTS AND METHODS: Between March 1998 and January 2002, 186 patients with a new diagnosis of cervical cancer underwent whole-body FDG-PET before therapy.
  • Fourteen patients had abnormal FDG uptake in left supraclavicular lymph nodes without palpable disease.
  • All 14 patients underwent sonographically guided fine-needle aspiration of the left supraclavicular lymph nodes.
  • One patient refused therapy, 6 were treated with palliative intent, and 7 received definitive irradiation and concurrent chemotherapy.
  • RESULTS: The overall frequency of FDG-positive left supraclavicular lymph nodes was 8% (14/186).
  • Therefore, the positive predictive value of abnormal FDG uptake in left supraclavicular lymph nodes was 100%.
  • Nineteen percent of all patients (35/186) had abnormal FDG uptake in para-aortic lymph nodes.
  • The frequency of positive FDG uptake in the left supraclavicular lymph nodes was 40% (14/35) in those with para-aortic lymph node uptake and 15% in those with stage IIIb disease.
  • All patients developed metastatic disease, most commonly to bone and lung.
  • CONCLUSION: The positive predictive value of abnormal FDG uptake in left supraclavicular lymph nodes was 100%.
  • Prognosis for these patients was dismal despite aggressive therapy.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymph Nodes / pathology. Radiopharmaceuticals. Uterine Neoplasms / radionuclide imaging
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Tomography, Emission-Computed

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 13678726.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


13. Oshima N, Tanizawa Y, Bando E, Kawamura T, Tokunaga M, Sugisawa N, Taki Y, Motegi Y, Boku N, Sasaki K, Terashima M: [Histological complete response in a case of advanced gastric cancer treated by neo-adjuvant chemotherapy with S-1/CDDP]. Gan To Kagaku Ryoho; 2010 Apr;37(4):697-701
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histological complete response in a case of advanced gastric cancer treated by neo-adjuvant chemotherapy with S-1/CDDP].
  • A 59-year-old male was found to have advanced gastric cancer with multiple lymph node metastasis including para-aortic lymph nodes(cT3, cN3, cM0, cH0, cP0, cStage IV).
  • Since curative surgery was deemed not feasible, we tried neoadjuvant chemotherapy expecting downstaging of the tumor.
  • Three courses of treatment resulted in a marked shrinkage of the primary lesion and a reduction of lymph nodes.
  • Laparotomy revealed neither ascites nor peritoneal dissemination, and he underwent total gastrectomy, splenectomy and D2+para-aortic lymph node dissection with curative intent.
  • The histological diagnosis revealed complete disappearance of cancer cells in the primary lesion of the stomach and lymph nodes, confirming a pathological complete response.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Neoadjuvant Therapy. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Drug Combinations. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414029.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Gadducci A, Cosio S, Zola P, Sostegni B, Ferrero AM, Teti G, Cristofani R, Sartori E: The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study. Gynecol Oncol; 2010 Mar;116(3):358-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study.
  • OBJECTIVES: To assess the clinical outcome of epithelial ovarian cancer patients who developed an apparently isolated lymph node recurrence after primary therapy.
  • METHODS: The authors retrospectively assessed 69 patients with epithelial ovarian cancer who were clinically or pathologically free of disease after primary therapy and who subsequently developed an apparently isolated lymph node recurrence.
  • RESULTS: Median age was 58 years, FIGO stage was III-IV in 52 (75%) patients, residual disease after primary surgery was >1 cm in 36 (52%), first-line chemotherapy consisted of paclitaxel-/platinum-based chemotherapy in 44 (64%), time to recurrence was >12 months in 43 (62%), recurrence was pelvic and/or para-aortic in 41 (59%), and treatment at recurrence consisted of chemotherapy alone in 44 (64%), surgery plus chemotherapy in 22 (32%), surgery alone in one patient, surgery plus irradiation in one, and irradiation alone in one patient.
  • Survival after recurrence was significantly related to the type of treatment (chemotherapy alone versus surgery plus chemotherapy, median: 20.8 months versus not reached, p=0.0002), and patient age (>58 versus <58 years, median: 26.8 versus 44.0 months, p=0.02).
  • Overall survival was significantly related to the type of treatment (chemotherapy alone versus surgery plus chemotherapy, median: 45.4 months versus not reached, p=0.0001), patient age (>58 versus <58 years, median: 45.4 versus 62.9 months, p=0.03) and time to recurrence (<12 months versus >12 months, median: 45.4 versus 66.9 months, p=0.01).
  • Cox model showed that treatment at recurrence was the strongest independent prognostic variable for both survival after recurrence (hazard ratio [HR]=0.277, p=0.0003) and overall survival (HR=0.249, p=0.0002).
  • CONCLUSION: Patients who underwent surgery plus chemotherapy had a 72% reduction in the risk of death after recurrence and a 75% reduction in the risk of death after initial diagnosis when compared with those treated with chemotherapy alone.
  • Secondary cytoreductive surgery appears to be able to prolong survival in epithelial ovarian cancer patients with apparently isolated lymph node recurrence.
  • [MeSH-major] Lymph Nodes / pathology. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Epithelial Cells / pathology. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Survival Rate


15. Sugawara H, Ichiki M, Sai K, Kamata K, Ansai M, Nakano Y, Kawamura M, Ichinose A, Miyazaki S: [Noticeable clinical response to S-1/CDDP combination therapy for Virchow node recurrence after surgery for advanced gastric carcinoma with marked involvement of the esophagus - report of a case]. Gan To Kagaku Ryoho; 2009 May;36(5):855-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Noticeable clinical response to S-1/CDDP combination therapy for Virchow node recurrence after surgery for advanced gastric carcinoma with marked involvement of the esophagus - report of a case].
  • We have recently experienced a case in which S-1/CDDP combination therapy proved remarkably efficacious for a rapid, extensive lymph node recurrence with metastasis into a Virchow node that had developed after resection of advanced gastric carcinoma accompanied with a marked invasion of the esophagus.
  • On day 65 post-operation, a diagnosis of Virchow node and para-aortic lymph node recurrence was made on the basis of CT scan findings.
  • The patient received three courses of S-1/CDDP combination therapy, with a consequent noticeable contraction of the Virchow node and enlarged para-aortic lymph node.
  • Further, she was given two courses of S-1 therapy, which resulted in normalization of tumor markers.
  • The patient has since been on continued chemotherapy without any sign of recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / secondary. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Drug Combinations. Female. Gastroscopy. Humans. Lymphatic Metastasis / pathology. Neoplasm Invasiveness / pathology. Neoplasm Staging. Recurrence. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461194.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Yoshida K, Ishikawa H, Sumida Y, Hara S, Kondou M, Hashizume S, Tokunaga T, Kamohara R, Minami H, Iwasaki K: [A case of N3 gastric cancer successfully treated by TS-1 followed by curative resection]. Gan To Kagaku Ryoho; 2006 Sep;33(9):1321-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Examination by computed tomography revealed gastric cancer and swollen para-aortic lymph nodes.
  • This patient was treated by neoadjuvant chemotherapy with oral administration of TS-1 (120 mg/day, day 1-28 with 2 weeks rest).
  • After 3 courses of TS-1, the primary lesion and swollen lymph nodes were remarkably reduced.
  • This chemotherapy enabled pancreatoduodenectomy with D 3 lymph node dissection in curative resection.
  • The pathological diagnosis was por, pT 2, pMP and pap, pT 1, pSM 2, pPM(-), pDM(-), pN 1, pStage II and curability A.
  • This neoadjuvant chemotherapy regimen seems to be an effective and promising therapy for patients with advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Gastrectomy. Lymph Node Excision. Lymph Nodes / pathology. Oxonic Acid / administration & dosage. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage
  • [MeSH-minor] Administration, Oral. Chemotherapy, Adjuvant. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Pancreaticoduodenectomy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969034.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


17. Ehara K, Tsutsumi K, Kinoshita Y, Ueno M, Mine S, Udagawa H: [A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU]. Gan To Kagaku Ryoho; 2008 Aug;35(8):1375-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU].
  • The combination chemotherapy with docetaxel/CDDP/5-FU(DCF)for head and neck squamous carcinoma(SCC) has been widely accepted.
  • It seems quite natural that DCF therapy is expected to be equally effective against esophageal SCC because of their histological similarity.
  • In this report, we present a case of unresectable advanced esophageal SCC with multiple liver metastases which showed remarkable regression by DCF therapy, with relatively slight adverse effects.
  • Abdominal CT scan showed multiple liver metastases with para-aortic lymph node involvement.
  • The clinical stage diagnosis was T3N4M1, Stage IVB, obviously non-resectable far-advanced esophageal SCC.
  • Systemic chemotherapy with DCF was started as the initial treatment.
  • The chemotherapy regimen was as follows.
  • Each course was followed by a 23-day drug-free period, and the entire course was repeated every 28 days.
  • Ten cycles of this DCF chemotherapy were carried out.
  • After 8 cycles, the liver metastases were judged as CR and para-aortic lymph nodes showed a partial response(PR)by CT scan.
  • Until this writing, we added 2 more cycles of DCF therapy for the recurrent para-aortic and inguinal lymph node metastasis.
  • We conclude that DCF therapy is potentially very effective for advanced esophageal SCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / pathology. Fluorouracil / therapeutic use. Liver Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Biomarkers, Tumor / blood. Esophagoscopes. Female. Humans. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed


18. Allan RW, Algood CB, Shih IeM: Metastatic epithelioid trophoblastic tumor in a male patient with mixed germ-cell tumor of the testis. Am J Surg Pathol; 2009 Dec;33(12):1902-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This report describes a rare case of a concurrent epithelioid trophoblastic tumor (ETT) and a teratoma in a para-aortic lymph node from a 39-year-old male patient with the initial diagnosis of testicular malignant mixed germ-cell tumor.
  • The metastatic lesion was excised 2 years after orchiectomy and chemotherapy.
  • Microscopically, the metastatic lesion contained a teratoma component and dispersed small nests of cohesive chorionic-type intermediate trophoblastic cells, closely resembling gestational ETT in female patients.
  • The diagnosis of ETT in this case was confirmed by stepwise immunohistochemistry.
  • Demonstration of ETT as one of the histologic manifestations of recurrent testicular germ-cell tumors should encourage pathologists to recognize this unique feature in assessing posttreatment mixed germ-cell neoplasm.
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Immunohistochemistry. Lymph Node Excision. Lymphatic Metastasis. Male. Orchiectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898219.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Takano M, Sasaki N, Kita T, Kudoh K, Fujii K, Yoshikawa T, Kato M, Hirata J, Furuya K, Tsuda H, Kikuchi Y: Survival analysis of ovarian clear cell carcinoma confined to the ovary with or without comprehensive surgical staging. Oncol Rep; 2008 May;19(5):1259-64
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pure-type clear cell carcinoma (CCC) has been recognized as a distinct subtype of ovarian cancer, showing a resistance to chemotherapy and resulting in poor prognosis.
  • Our aim was to evaluate the effects of complete surgical procedures followed by adjuvant chemotherapy for CCC patients whose tumors were confined to the ovary (pT1M0).
  • During the period of 1987-2005, 56 patients with stage I CCC were identified and two cases were excluded due to retroperitoneal lymph node metastasis.
  • A total of 54 patients were enrolled in the study and divided into two groups: Group A (n=38, 1993-2005) underwent complete surgical staging including pelvic and para-aortic lymphadenectomy.
  • Every patient received six courses of adjuvant chemotherapy using a platinum agent.
  • The clinical characteristics of the two groups were similar, except for the rate of conventional platinum-based chemotherapy (p=0.02).
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / mortality. Neoplasm Staging. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Metastasis. Prognosis. Proportional Hazards Models. Regression Analysis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425385.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


20. Southcott BM: Carcinoma of the endometrium. Drugs; 2001;61(10):1395-405
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence rises with age and is significantly increased when there is exposure to unopposed estrogen, including hormone replacement therapy (HRT).
  • Transvaginal ultrasound and pipelle or hysteroscopy endometrial biopsies are tending to replace the traditional dilation and curettage in establishing a diagnosis.
  • Prognostic factors include the histological grade, the depth of invasion of the myometrium, the presence or absence of lymph-vascular space invasion and involved regional nodes, tumour volume, and the presence or absence of involvement of the cervix.
  • The pelvis is a major anatomical site at risk of recurrence, and since cytotoxic chemotherapy and hormone therapies have limited effectiveness, radiotherapy is the adjuvant therapy of choice where adverse prognostic factors are present.
  • A move towards more radical surgery--the addition of lymphadenectomy with a total abdominal hysterectomy and bi-lateral salpingo oophorectomy, may modify the value of adjuvant therapy and has highlighted the need to demonstrate the exact place of post operative radiotherapy in the management of endometrial cancer.
  • Spread outside the pelvis to para-aortic nodes may still be salvaged with local irradiation, but systemic disease is incurable and treatment is largely palliative including consideration of local irradiation, hormone therapy or chemotherapy for symptomatic relief.
  • As reliable techniques for diagnosis are refined an even larger proportion of patients will be diagnosed with early disease.
  • This, together with the development of new cytotoxic agents and sophisticated radiotherapy techniques to reduce normal tissue morbidity, will require the establishment of further clinical trials to refine optimal management.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Hormone Replacement Therapy / adverse effects. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Metastasis. Prognosis. Radiotherapy, Adjuvant. Risk Factors. Salvage Therapy. Tamoxifen / adverse effects

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1994 Jul;84(1):12-6 [8008305.001]
  • [Cites] Obstet Gynecol. 1979 Jul;54(1):85-9 [450367.001]
  • [Cites] Gynecol Oncol. 1974 Aug;2(2-3):368-76 [4616883.001]
  • [Cites] Am J Dermatopathol. 1996 Feb;18(1):94-8 [8721599.001]
  • [Cites] Gynecol Oncol. 1999 Jul;74(1):118-22 [10385562.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):570-6 [10027332.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):422-3 [10366471.001]
  • [Cites] Eur J Cancer Clin Oncol. 1987 Jul;23(7):1025-9 [3665988.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Nov 15;27(4):817-24 [8244810.001]
  • [Cites] Gynecol Oncol. 1997 Jun;65(3):530-3 [9190989.001]
  • [Cites] J Am Podiatr Med Assoc. 1996 Jul;86(7):331-3 [8757485.001]
  • [Cites] Cancer. 1987 May 1;59(9):1665-9 [3828966.001]
  • [Cites] Gynecol Oncol. 1999 Feb;72(2):261-4 [10021312.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 7;91(13):1131-7 [10393721.001]
  • [Cites] Hum Reprod. 1999 May;14(5):1381-3 [10325299.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1992 Nov;4(6):373-6 [1463690.001]
  • [Cites] Acta Obstet Gynecol Scand. 1986;65(3):247-55 [3739631.001]
  • [Cites] Br J Cancer. 1984 Nov;50(5):687-92 [6498067.001]
  • [Cites] Acta Oncol. 1990;29(2):203-9 [2185804.001]
  • [Cites] Eur J Gynaecol Oncol. 1993;14(5):425-36 [8253106.001]
  • [Cites] Clin Radiol. 1985 Nov;36(6):619-23 [4064547.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(2):87-9 [10376419.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):407-11 [10366468.001]
  • [Cites] J Chronic Dis. 1987;40 Suppl 2:59S-69S [3667868.001]
  • [Cites] Br J Hosp Med. 1995 Sep 6-19;54(5):198-201 [8528525.001]
  • [Cites] Obstet Gynecol. 1981 Nov;58(5):590-5 [7301235.001]
  • [Cites] Histopathology. 1999 Jan;34(1):51-5 [9934584.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(2):156-9 [10376438.001]
  • [Cites] Eur J Gynaecol Oncol. 1996;17(6):520-1 [8971533.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1999;11(4):252-4 [10473722.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(1):8-12 [10422671.001]
  • [Cites] Med Oncol Tumor Pharmacother. 1985;2(3):125-35 [4068799.001]
  • [Cites] Eur J Gynaecol Oncol. 1997;18(6):492-4 [9443018.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):320-7 [9010105.001]
  • [Cites] Am J Obstet Gynecol. 1987 Jul;157(1):35-40 [3605266.001]
  • [Cites] Am J Clin Nutr. 1987 Jan;45(1 Suppl):283-9 [3799518.001]
  • [Cites] Am J Obstet Gynecol. 1987 Jan;156(1):20-3 [3799753.001]
  • [Cites] Strahlenther Onkol. 1991 Jul;167(7):381-6 [1858012.001]
  • [Cites] Maturitas. 1999 Mar 15;31(3):237-40 [10340283.001]
  • [Cites] Obstet Gynecol. 1991 Dec;78(6):1033-8 [1945203.001]
  • [Cites] Mater Med Pol. 1995 Jan-Mar;27(1):23-5 [8569272.001]
  • [Cites] Anticancer Res. 1996 Jan-Feb;16(1):475-9 [8615657.001]
  • [Cites] Surg Gynecol Obstet. 1971 May;132(5):855-60 [5555407.001]
  • [Cites] Surg Clin North Am. 1991 Oct;71(5):991-1004 [1925858.001]
  • [Cites] Curr Opin Obstet Gynecol. 1994 Feb;6(1):92-7 [8180358.001]
  • [Cites] Lancet. 2000 Sep 9;356(9233):881-7 [11036892.001]
  • [Cites] Obstet Gynecol. 1980 Oct;56(4):419-27 [6999399.001]
  • [Cites] JAMA. 1996 Feb 7;275(5):370-5 [8569016.001]
  • [Cites] Lancet. 2000 Apr 22;355(9213):1404-11 [10791524.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1996;8(3):140-5 [8814367.001]
  • (PMID = 11558829.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 57
  •  go-up   go-down


21. Sood BM, Jones J, Gupta S, Khabele D, Guha C, Runowicz C, Goldberg G, Fields A, Anderson P, Vikram B: Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys; 2003 Sep 1;57(1):208-16
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.
  • The majority of patients with clinical Stage I UPSC are found to have extrauterine disease at the time of surgery.
  • Surgical treatment as the sole therapy for patients with Stage I-IV UPSC is unacceptable because of high recurrence rates.
  • Chemotherapy, radiotherapy, or both have been added after surgery in an attempt to improve survival.
  • However, the survival benefit to patients from such multimodality therapy remains uncertain.
  • This study analyzes the patterns of failure in patients with FIGO Stages I-IV UPSC treated by multimodality therapy.
  • METHODS AND MATERIALS: Forty-two women with FIGO Stages I-IV UPSC who were treated by multimodality therapy were analyzed retrospectively between 1988 and 1998.
  • Data were obtained from tumor registry, hospital, and radiotherapy chart reviews, operative notes, pathology, and chemotherapy flow sheets.
  • All the patients underwent staging laparotomy, peritoneal cytology, total abdominal hysterectomy and salpingo oophorectomy, pelvic and para-aortic lymph node sampling, omentectomy, and cytoreductive surgery, when indicated followed by radiotherapy and/or chemotherapy.
  • Therapy consisted of external beam radiation therapy in 11 patients (26%), systemic chemotherapy in 20 (48%), and both radiotherapy and chemotherapy in 11 (26%).
  • The treatments were not assigned in a randomized fashion.
  • The dose of external beam radiation therapy ranged from 45-50.40 Gy (median 45).
  • Of the 31 patients (74%) who received chemotherapy, 18 received single-agent (58%), whereas 13 received multiagent chemotherapy (42%).
  • Twenty-nine patients (69%) had suffered recurrence at the time of last follow-up.
  • Twenty-five patients (60%) had died at the time of reporting; the observed survival rate at 2 years and 5 years was 52% and 43%, respectively.
  • CONCLUSIONS: Our data suggest that, after multimodality therapy of FIGO Stage I-IV UPSC, most patients developed abdominopelvic (locoregional) failure, and the great majority of the failures occurred in the abdomen, vagina, and pelvis (66%).
  • Distant failure alone occurred in 17% of the patients.We propose that future studies should combine whole abdominal radiotherapy (WART) with pelvic and vaginal boosts, in addition to chemotherapy for FIGO Stage I-IV UPSC, especially in patients with minimal residual disease, to attempt to improve the dismal prognosis of patients with UPSC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cystadenocarcinoma, Papillary / mortality. Cystadenocarcinoma, Papillary / therapy. Neoplasm Recurrence, Local / diagnosis. Uterine Neoplasms / mortality. Uterine Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Cisplatin / administration & dosage. Combined Modality Therapy / methods. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging / methods. Paclitaxel / administration & dosage. Retrospective Studies. Shiga Toxins / administration & dosage. Survival Analysis. Treatment Failure

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12909235.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Shiga Toxins; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Chalkiadakis GE, Lasithiotakis KG, Petrakis I, Kourousis C, Georgoulias V: Major hepatectomy and right hemicolectomy at the time of primary cytoreductive surgery for advanced ovarian cancer: report of a case. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1115-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Major hepatectomy and right hemicolectomy at the time of primary cytoreductive surgery for advanced ovarian cancer: report of a case.
  • Major liver involvement at the time of diagnosis is a rare event in patients with ovarian cancer, and the issue of major hepatectomy at the time of primary cytoreductive surgery is controversial.
  • A computed tomography scan demonstrated bilateral ovarian masses, extending to the right iliac fossa, pressing the cecum-ascending colon.
  • The diagnosis of advanced ovarian cancer was clinically suspected; the patient underwent a total abdominal hysterectomy with bilateral salpingo-oophorectomy, right hemicolectomy, omentectomy, left lobectomy, deroofing, and draining of the cystic formation of the right liver lobe along with systematic pelvic and para-aortic lymphadenectomy.
  • Systemic chemotherapy (six cycles of paclitaxel/carboplatin) was subsequently administered, and after 15 months of follow-up period, the patient is still in first remission and alive.
  • Ovarian cancer with concomitant extensive right colon infiltration and hematogenous liver metastases can be successfully managed with aggressive surgical resection and postoperative chemotherapy in carefully selected patients.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Female. Gynecologic Surgical Procedures. Humans. Lymph Node Excision. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343191.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


23. Hofmann U, O'Connor JP, Biyani CS, Harnden P, Selby P, Weston PM: Retroperitoneal metastatic squamous cell carcinoma of the tonsil (with elevated beta human chorionic gonadotrophin): a misdiagnosis as extra-gonadal germ cell tumour. J Laryngol Otol; 2006 Oct;120(10):885-7
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Head and neck cancers usually spread first to the regional lymph nodes but rarely may metastasize to distant sites.
  • Metastasis to distant lymph node groups is a rare event.
  • A computed tomography scan demonstrated para-aortic retroperitoneal lymphadenopathy.
  • The patient underwent an open lymph node biopsy.
  • The initial pathological analysis was interpreted as extra-gonadal germ cell tumour and the patient received chemotherapy.
  • Following this, the chemotherapy regimen was changed; however, a restaging scan demonstrated progression, and the patient died from aspiration pneumonia secondary to alcohol intoxication.
  • This case highlights the necessity of using clinical, histological, immunohistological and ultrastructural examination to establish precise diagnosis and to avoid inappropriate treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Diagnostic Errors. Neoplasms, Germ Cell and Embryonal / diagnosis. Retroperitoneal Neoplasms / diagnosis. Tonsillar Neoplasms
  • [MeSH-minor] Chorionic Gonadotropin, beta Subunit, Human / blood. Fatal Outcome. Humans. Hydronephrosis / complications. Male. Middle Aged. Neoplasm Proteins / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16716237.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / Neoplasm Proteins
  •  go-up   go-down


24. Kuscu E, Oktem M, Haberal A, Erkanli S, Bilezikci B, Demirhan B: Management of advanced-stage primary carcinoma of the fallopian tube: case report and literature review. Eur J Gynaecol Oncol; 2003;24(6):557-60
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 55-year-old, gravida 7, para 3 woman presented with no gynecologic complaints other than backache.
  • Pelvic lymph node metastases were observed.
  • Total abdominal hysterectomy, bilateral salpingo-oophorectomy, appendectomy, omentectomy, pelvic and para-aortic lymph node dissection, and peritoneal washing were performed.
  • The definitive histopathological diagnosis was primary serous adenocarcinoma of the fallopian tube with six of 25 lymph node biopsies showing metastasis.
  • Six cycles of paclitaxel (175 mg/m2) plus cisplatin (75 mg/m2) combinatin chemotherapy were administered with 3-week intervals between cycles.
  • At the time of writing 12 months after the second-look laparotomy, she was still disease-free.
  • [MeSH-major] Cystadenocarcinoma, Serous / diagnosis. Fallopian Tube Neoplasms / diagnosis. Pelvic Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aorta, Thoracic. Appendectomy. Cisplatin / administration & dosage. Diagnosis, Differential. Fallopian Tubes / surgery. Female. Humans. Hysterectomy. Lymph Nodes / surgery. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Omentum / surgery. Ovariectomy. Paclitaxel / administration & dosage. Second-Look Surgery

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14658603.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 40
  •  go-up   go-down


25. Ruvalcaba-Limón E, Cantú-de-León D, León-Rodríguez E, Cortés-Esteban P, Serrano-Olvera A, Morales-Vásquez F, Sosa-Sánchez R, Poveda-Velasco A, Crismatt-Zapata A, Santillán-Gómez A, Aguilar-Jiménez C, Alanís-López P, Alfaro-Ramírez P, Alvarez-Avitia MA, Aranda-Flores CE, Arias-Ceballos JH, Arrieta-Rodríguez O, Barragán-Curiel E, Botello-Hernández D, Brom-Valladares R, Cabrera-Galeana PA, Cantón-Romero JC, Capdeville-García D, Cárdenas-Sánchez J, Castorena-Roji G, Cepeda-López FR, Cervantes-Sánchez G, Cetina-Pérez Lde C, Coronel-Martínez JA, Cortés-Cárdenas SA, Cruz-López JC, de la Garza-Salazar JG, Díaz-Romero C, Dueñas-González A, Valle-Solís AE, Escudero-de los Ríos P, Flores-Alvarez E, García-Matus R, Gerson-Cwilich R, González-Enciso A, González-de-León C, Guevara-Torres AG, Herbert-Núñez GS, Hernández-Hernández C, Hernández-Hernández DM, Isla-Ortiz D, Jesús-Sandoval R, Jiménez-Cervantes C, Kuri-Exsome R, López-Obispo JL, Maffuz-Aziz A, Martínez-Barrera LM, Medina-Castro JM, Montalvo-Esquivel G, Mora-Aguilar VH, Morales-Palomares MA, Morán-Mendoza A, Morgan-Villela G, Mota-García A, Muñoz-González DE, Murillo-Cruz DA, Novoa-Vargas A, Ochoa-Carrillo FJ, Oñate-Ocaña LF, Ortega-Rojo A, Palacios-Martínez AG, Palomeque-López A, Pérez-Montiel MD, Quijano-Castro F, Rivera-Rivera S, Rivera-Rubí LM, Robles-Flores JU, Rodríguez-Trejo A, Salas-Gonzáles E, Silva JA, Solorza-Luna G, Souto-del-Bosque R, Tirado-Gómez LL, Torrescano-González S, Torres-Lobatón A, Trejo-Durán E, Villavicencio-Valencia V, Gallardo-Rincón D, Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México: [The first Mexican consensus of endometrial cancer. Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México]. Rev Invest Clin; 2010 Nov-Dec;62(6):583, 585-605
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GICOM collaborative group under the auspice of different institutions have made the following consensus in order to make recommendations for the management of patients with this type of neoplasm.
  • RESULTS: Screening should be performed women at high risk (diabetics, family history of inherited colon cancer, Lynch S. type II).
  • Diagnosis is made by histerescopy-guided biopsy.
  • Total abdominal hysterectomy, bilateral salpingo oophorectomy, pelvic and para-aortic lymphadenectomy should be performed except in endometrial histology grades 1 and 2, less than 50% invasion of the myometrium without evidence of disease out of the uterus.
  • Adjuvant treatment after surgery includes radiation therapy to the pelvis, brachytherapy, and chemotherapy.
  • Patients with Stages III and IV should have surgery with intention to achieve optimal cytoreduction because of the impact on survival (51 m vs. 14 m), the treatment of recurrence can be with surgery depending on the pattern of relapse, systemic chemotherapy or hormonal therapy.
  • Multidisciplinary treatment impacts on survival and local control of the disease, including surgery, radiation therapy and chemotherapy, hormonal treatment is reserved to selected cases of recurrence.
  • This is the first attempt of a Mexican Collaborative Group in Gynecology to give recommendations is a special type of neoplasm.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnostic Imaging. Estrogen Antagonists / adverse effects. Estrogen Replacement Therapy / adverse effects. Estrogens / adverse effects. Evidence-Based Medicine. Female. Humans. Hysterectomy / methods. Laparoscopy. Lymph Node Excision. Mass Screening. Mexico. Neoplasm Staging / methods. Radiotherapy, Adjuvant. Risk Factors. Salvage Therapy. Tamoxifen / adverse effects

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21416918.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] spa
  • [Publication-type] Consensus Development Conference; English Abstract; Journal Article; Practice Guideline
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Estrogen Antagonists; 0 / Estrogens; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


26. Koukourakis G, Kouloulias V: Lymphoma of the testis as primary location: tumour review. Clin Transl Oncol; 2010 May;12(5):321-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-Hodgkin's lymphoma as a primary testicular neoplasm accounts approximately 9% of all testicular malignant tumours and about 1-2% of all non-Hodgkin's lymphoma.
  • This neoplasm is the most common malignant tumour of the testis in the elderly.
  • In more advanced stages with para-aortic lymph-node involvement, ascites and abdominal pain is evident.
  • Despite the fact that responses to doxorubicin- containing chemotherapy, especially in early stages, show good results, relapses are often seen, and the prognosis of this tumour is very poor.
  • Testicular lymphoma often disseminates to other extranodal organs, such as contralateral testis, central nervous system (CNS), lung, pleura, Waldeyer's ring and soft tissue.
  • For patients with limited disease, the recommended first-line treatment is orchiectomy followed by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) combination chemotherapy, with central nervous system (CNS) prophylaxis and prophylactic irradiation of the contralateral testis.
  • [MeSH-major] Lymphoma / diagnosis. Lymphoma / therapy. Testicular Neoplasms / diagnosis. Testicular Neoplasms / therapy
  • [MeSH-minor] Disease Progression. Humans. Male. Neoplasm Metastasis. Neoplasm Staging / methods. Prognosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):20-7 [12506165.001]
  • [Cites] Clin Lymphoma. 2001 Jun;2(1):40-6 [11707869.001]
  • [Cites] Br J Urol. 1974 Oct;46(5):569-75 [4420636.001]
  • [Cites] Neth J Med. 1991 Aug;39(1-2):92-100 [1961354.001]
  • [Cites] Acta Radiol Oncol Radiat Phys Biol. 1979;18(6):572-76 [543449.001]
  • [Cites] Am J Med. 1986 Sep;81(3):515-24 [3529957.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):197-204 [11773170.001]
  • [Cites] Blood. 2005 Jan 15;105(2):496-502 [15358629.001]
  • [Cites] Neurol Med Chir (Tokyo). 1986 Jan;26(1):68-70 [2425280.001]
  • [Cites] Oncology. 2000 May;58(4):286-92 [10838493.001]
  • [Cites] J Urol. 1969 Aug;102(2):230-2 [4895868.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5027-33 [15955905.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1578-84 [6989476.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):154-61 [10618618.001]
  • [Cites] Clin Lymphoma. 2001 Sep;2(2):109-15 [11707851.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):652-6 [11849786.001]
  • [Cites] Am J Surg Pathol. 1994 Apr;18(4):376-90 [8141430.001]
  • [Cites] Clin Lymphoma. 2002 Dec;3(3):167-72 [12521394.001]
  • [Cites] Australas Radiol. 1991 Aug;35(3):257-60 [1763988.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2854-8 [10561362.001]
  • [Cites] Ann Oncol. 1990 Sep;1(5):383 [2261381.001]
  • [Cites] J Urol. 1977 Nov;118(5):783-6 [916101.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):73-7 [7819053.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1361-7 [7751880.001]
  • [Cites] Eur Urol. 2000 Dec;38(6):774-7 [11111200.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):129-33 [14679132.001]
  • [Cites] J Urol. 1994 May;151(5):1162-70 [8158751.001]
  • [Cites] J Urol. 1996 Mar;155(3):943-6 [8583613.001]
  • [Cites] Radiother Oncol. 1993 May;27(2):99-106 [8356234.001]
  • [Cites] Eur J Cancer. 1994;30A(12):1760-4 [7880601.001]
  • [Cites] J Pak Med Assoc. 1994 Apr;44(4):86-8 [8072129.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1182-6 [7850719.001]
  • [Cites] J Urol. 1977 Dec;118(6):1004-7 [336911.001]
  • [Cites] Int J Oncol. 2005 Apr;26(4):1093-9 [15754007.001]
  • [Cites] Nouv Rev Fr Hematol. 1995;37(5):267-72 [8700650.001]
  • [Cites] Oncology (Williston Park). 1998 Feb;12(2):185-91; discussion 192-5 [9507520.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]
  • [Cites] Acta Oncol. 2004;43(8):758-65 [15764222.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):259-69 [10375083.001]
  • (PMID = 20466616.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 44
  •  go-up   go-down


27. Lee S, Park SY, Hong EK, Ro JY: Lymphoepithelioma-like carcinoma of the ovary: a case report and review of the literature. Arch Pathol Lab Med; 2007 Nov;131(11):1715-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 51-year-old woman presenting with low abdominal pain was found to have a right ovarian mass and enlarged pelvic, left para-aortic, and left supraclavicular lymph nodes.
  • Based on a clinical diagnosis of right ovarian carcinoma with lymph node metastases, she received 9 cycles of chemotherapy, resulting in a reduction of her ovarian tumor, disappearance of the enlarged pelvic and para-aortic lymph nodes, and normalization of serum CA 125 level.
  • However, there was no viable tumor in either supraclavicular or para-aortic lymph nodes.
  • [MeSH-major] Carcinoma / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. CA-125 Antigen / blood. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979492.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CA-125 Antigen
  • [Number-of-references] 16
  •  go-up   go-down


28. Lackman F, Carey MS, Kirk ME, McLachlin CM, Elit L: Surgery as sole treatment for serous borderline tumors of the ovary with noninvasive implants. Gynecol Oncol; 2003 Aug;90(2):407-12
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery as sole treatment for serous borderline tumors of the ovary with noninvasive implants.
  • All patients underwent surgical treatment including staging and their pathology was reviewed.
  • No patient was treated with adjuvant therapy (radiation or chemotherapy) after surgical treatment and none were lost to follow-up.
  • RESULTS: The mean age at diagnosis was 42 years (range 26-59).
  • Two patients underwent pelvic and para-aortic lymph node dissection.
  • All patients but 2 had clinical evidence of extraovarian disease at the time of surgery.
  • Two patients have been treated with chemotherapy (paclitaxel/carboplatin) for progressive borderline disease, while an additional patient was treated after first relapse with chemotherapy for an invasive recurrence.
  • CONCLUSIONS: Carefully staged patients with advanced serous borderline tumors of the ovary and noninvasive implants have a good prognosis without adjuvant therapy.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cohort Studies. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12893209.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


29. Haie-Meder C, Mazeron R, Magné N: Clinical evidence on PET-CT for radiation therapy planning in cervix and endometrial cancers. Radiother Oncol; 2010 Sep;96(3):351-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical evidence on PET-CT for radiation therapy planning in cervix and endometrial cancers.
  • PET-CT plays an increasing role in the diagnosis and treatment of gynaecological cancers.
  • In cervix cancer, whilst MRI remains the best imaging technique for initial primary tumor staging, PET-CT has been showed to be a highly sensitive method to determine lymph node status, except in patients with early-stage cervical cancer where PET-CT cannot replace surgical exploration of pelvic lymph nodes.
  • In patients with advanced cervical cancer, PET-CT has the potential of showing lymph node metastasis not only within the pelvis, but also outside the pelvis, more particularly in the para-aortic area.
  • In endometrial cancer, the issues are different, as the recent decade has seen a therapeutic decrease in early-stage disease, especially in postoperative radiation therapy, whilst more advanced disease have been approached with more aggressive treatments, integrating chemotherapy and external beam radiotherapy.
  • Lymph node status is also an important issue and PET-Scan may replace lymph node surgical procedure particularly in obese patients.
  • [MeSH-major] Endometrial Neoplasms / radiotherapy. Positron-Emission Tomography / methods. Radiotherapy Planning, Computer-Assisted / methods. Tomography, X-Ray Computed / methods. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Brachytherapy. Female. Humans. Lymphatic Metastasis. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Society for Therapeutic Radiology and Oncology and European Association of Nuclear Medicine. Published by Elsevier Ireland Ltd.. All rights reserved.
  • (PMID = 20709417.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  •  go-up   go-down






Advertisement